FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40 | -65.2% | 19,031 | -21.5% | 0.00% | -100.0% |
| Q2 2023 | $115 | -79.2% | 24,251 | -75.1% | 0.00% | -80.0% |
| Q1 2023 | $554 | -77.7% | 97,235 | -60.4% | 0.01% | -86.1% |
| Q4 2022 | $2,480 | -99.6% | 245,758 | +864.7% | 0.04% | +414.3% |
| Q3 2022 | $571,000 | -29.6% | 25,474 | +86.1% | 0.01% | -36.4% |
| Q3 2021 | $811,000 | -6.8% | 13,686 | +36.6% | 0.01% | +10.0% |
| Q2 2021 | $870,000 | -29.9% | 10,020 | -26.6% | 0.01% | -16.7% |
| Q4 2020 | $1,241,000 | +364.8% | 13,651 | +13.6% | 0.01% | -20.0% |
| Q1 2020 | $267,000 | – | 12,014 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |